

**Osler, Hoskin & Harcourt LLP**  
Box 50, 1 First Canadian Place  
Toronto, Ontario, Canada M5X 1B8  
416.362.2111 MAIN  
416.862.6666 FACSIMILE

OSLER

Toronto

July 19, 2024

Montréal

Calgary

City Clerk  
Toronto City Council  
100 Queen Street West, 2nd Floor, West Tower  
Toronto ON M5H 2N2

Ottawa

Vancouver

New York

Re: North York Community Council  
Item NY15.4: 1875 Steeles Ave W  
Planning Applications: 20 213392 NNY 06 OZ, 20 213295 NNY 06 RH

We act on behalf of Sanofi Pasteur Limited<sup>1</sup> (“Sanofi”), the owners of 1755 Steeles Ave W, where it operates a large, 54-acre biopharmaceutical manufacturing and research campus with over 40 buildings (the “Sanofi Property”). Sanofi made a written submission to the North York Community Council, a copy of which is attached.

We understand that the applicant in this matter has requested that their application be referred to staff for further consideration. While Sanofi has met with the applicant, and will continue to do so regardless of Council’s decision in this matter, it remains opposed to the scale and scope of the proposed re-zoning for the reasons set out in the attached letter.

The Sanofi property, operating at this location for more than 100 years, is a globally significant research and development and biomanufacturing facility, which operates 24/7/365. It is home to the largest vaccine manufacturing facility in Canada and plays a critical role in public health with recent significant (\$540 million) investments from the Government of Canada and the Province of Ontario as well as collaboration with the City of Toronto, to provide expanded domestic vaccine production and pandemic readiness for Canada and beyond. Sanofi appreciates the efforts by Tenblock to understand and attempt to address Sanofi’s concerns. While Sanofi has taken into consideration the information that Tenblock and its consultants have provided, it cannot accept the introduction of thousands of new residents so close to its existing facilities and the impacts this will have on the ability to attract global manufacturing and R&D mandates in the future. Without limiting the concerns that Sanofi has raised, we address some of the specific issues in more detail below.

---

<sup>1</sup> Sanofi is a “specified person” as defined in the *Planning Act*, being the holder of Environmental Compliance Approvals in an employment area within 300 metres of the proposed rezoning at 1875 Steeles.

*Security*

Sanofi has met with Tenblock and their security consultants, Juno. Sanofi's security team has reviewed the conclusions Juno has reached. Given Sanofi's knowledge of its own operations and security risk profile (the nature and details of which of necessity must remain confidential), it continues to have fundamental concerns with the increased risk posed by the proposed development. As noted by Councillor Burnside at the North York Community Council meeting, Sanofi knows its own business better than external consultants. On this issue in particular, Sanofi does not agree with or accept the increased risk to the security of all aspects of its operations if this application is approved.

*Noise*

The technical work completed in support of the application indicates that the Class 1 noise level limits are exceeded between 11 p.m. and 7 a.m. at the proposed residences, and that mitigating the noise from Sanofi to meet the Class 1 limits is not practical.

The solution of increasing the noise level limits to Class 4 may be technically achievable but the fundamental question for Council is whether the standards should be shifted to permit this development. It is entirely within Council's discretion to decide whether, in light of the unique circumstances of the Sanofi operations, it wants to create an environment where the permitted noise level is effectively doubled.

Sanofi has no doubt that a Class 4 designation and increased residents will result in increased complaints, and any warning clauses or other agreements do not and cannot mitigate that risk to Sanofi. Responding to complaints diverts resources from its operations. It also creates an environment whereby future investments in the site are less likely, harming Toronto and Canada's competitiveness for high quality jobs in the biotechnology field.

Having reviewed all of the material submitted in support of the application, Sanofi continues to be of the view that the zoning by-law amendment application should be refused. The national and global importance of Sanofi's Toronto campus' contribution to public health and pandemic preparedness, and its ability to sustain current, and attract future, R&D and biomanufacturing mandates, jobs and investments to Toronto cannot be undermined or curtailed by the constraints that will result from the scale and scope of this proposed residential development.

We ask that we be given notice of any decision with respect to this application.

Yours very truly,

A handwritten signature in black ink, appearing to read "Chris Barnett". The signature is fluid and cursive, with a prominent flourish at the end.

Chris Barnett  
Partner

Cc: Sanofi Pasteur Limited  
Anne Benedetti – Goodmans LLP, counsel for the applicant

Attachment: July 8, 2024 letter to North York Community Council

Toronto

Montréal

Calgary

Ottawa

Vancouver

New York

July 8, 2024

City Clerk, Attention: Matthew Green  
Administrator, North York Community Council  
100 Queen Street West, 2nd Floor, West Tower  
Toronto ON M5H 2N2

Re: North York Community Council  
Item NY15.4: 1875 Steeles Ave W  
Planning Applications: 20 213392 NNY 06 OZ, 20 213295 NNY 06 RH

We act on behalf of Sanofi Pasteur Limited<sup>1</sup> (“Sanofi”), the owners of 1755 Steeles Ave W, where it operates a large biopharmaceutical manufacturing and research campus (the “Sanofi Property”). An aerial photograph showing the Sanofi Property and surrounding area is attached.

### *Summary*

On May 30, 2024, Prime Minister Trudeau, Premier Ford, Mayor Chow and Councillor Pasternak, along with other federal and provincial ministers attended the opening of Canada’s largest biomanufacturing building located within the Sanofi Property.<sup>2</sup> Adding to Sanofi’s 100+ year heritage on the campus, the new building will produce pediatric and adult vaccines that will serve Canada and the global market. Sanofi is also constructing a new end-to-end influenza vaccine manufacturing facility with pandemic readiness capabilities in partnership with all levels of government, with both projects receiving up to \$540 million in public funding. This investment will help Canada respond to future public health emergencies such as pandemics by producing vaccines domestically.

The re-zoning application for 960 new residences in buildings up to 39 storeys located within 103 metres of Sanofi’s facility is incompatible with Sanofi’s vital operations, and has the potential to limit Sanofi’s ability to operate at full capacity, as well as limit its ability to expand its operations in the future. As an affiliate of a global multinational company, the Sanofi Property’s capabilities must be seen as having a competitive advantage to secure public health manufacturing mandates locally.

---

<sup>1</sup> Sanofi is a “specified person” as defined in the *Planning Act*, being the holder of Environmental Compliance Approvals in an employment area within 300 metres of the proposed rezoning at 1875 Steeles.

<sup>2</sup> Press releases from the event are attached.



Sanofi is opposed to the approval of the re-zoning on the basis that it is inconsistent with provincial policies that protect existing industry and its ability to expand in the future. The proposed residences do not meet provincial noise guidelines based on the noise from Sanofi's operations. The proposed designation of the property as Class 4 underscores that high rise residences so close to noisy operations are incompatible and should not be approved.

As referenced above, Sanofi is in the process of expanding its facilities on the Subject Property to include vital national and globally important vaccine manufacturing capacity. This additional capacity will be available to Canada in the event of any future urgent need for domestic or global pandemic vaccine production capacity. These facilities are located immediately to the east and south of the sites that are the subject of the above noted Planning Act application (the "Subject Application"). This side of Sanofi's campus has considerable activity, including year-round, 24 hours per day, large truck deliveries, including weekends.

We write to express Sanofi's objection to the staff recommendation to approve the Subject Application.

*Background and context*

The Sanofi Property is approximately 21 ha in size, and comprised of over forty buildings. Medical and biopharmaceutical research and manufacturing have been located here for over 100 years, and this has been home to many significant innovations and production for global public health mandates, including contribution to the first purification and mass production of insulin, war efforts, diphtheria, tetanus, pertussis, polio, cancer and combination vaccines. The Subject Property is designated as Core Employment in the Official Plan, and is part of the Toronto-York Provincially Significant Employment Zone. In 2012, the City approved an OPA and zoning amendment to permit the expansion of Sanofi's operations, converting land from a Neighbourhood designation to Employment Area. It currently provides over 2,000 full-time jobs, with a further 1,000 jobs, including contractors.

While Sanofi's operations generate noise, it operates its facilities in accordance with Environmental Compliance Approvals issued by the Ministry of Environment, Conservation and Parks. Its operations include mitigation measures that take into consideration the low rise residential development to the north and east of the Subject Property, and are in compliance with all applicable laws with respect to noise.

Sanofi's ability to continue to operate and expand its vital operations on the subject site must not be impeded by the introduction of new sensitive uses as proposed by the Subject Application. The Sanofi Property is part of the company's and all level of governments' recent investments totaling \$2 billion in the future of Ontario and Canada's



biomanufacturing sector. As such, Sanofi's Toronto campus continually needs to update, modify and expand as science, technology and innovation advances in a globally competitive environment. Limitations on Sanofi's ability to expand in the future may result in R&D and manufacturing mandates not being considered in Toronto, as other jurisdictions compete for bringing these investments and jobs.

Sanofi takes the position that the Subject Applications should not be approved, as they are not consistent with the *Provincial Policy Statement (2020)*, and do not conform with either A Place to Grow or Toronto's Official Plan. The Subject Applications encroach on Sanofi's operations and ability to expand consistent with its long term plans for the Subject Site.

*Proposals are not consistent with the Provincial Policy Statement (2020)*

The Subject Property is considered a "major facility" as defined in the PPS.

The PPS was amended in 2020 to include express protections to existing major facilities to further protect their ability to operate, and from the encroachment of sensitive uses. In particular, policy 1.2.6 states that:

**1.2.6.1** *Major facilities and sensitive land uses* shall be planned and developed to avoid, or if avoidance is not possible, minimize and mitigate any potential *adverse effects* from odour, noise and other contaminants, minimize risk to public health and safety, and to ensure the long-term operational and economic viability of *major facilities* in accordance with provincial guidelines, standards and procedures.

**1.2.6.2** Where avoidance is not possible in accordance with policy 1.2.6.1, planning authorities shall protect the long-term viability of existing or planned industrial, manufacturing or other uses that are vulnerable to encroachment by ensuring that the planning and *development* of proposed adjacent *sensitive land uses* are only permitted if the following are demonstrated in accordance with provincial guidelines, standards and procedures:

- a) there is an identified need for the proposed use;
- b) alternative locations for the proposed use have been evaluated and there are no reasonable alternative locations;
- c) *adverse effects* to the proposed sensitive land use are minimized and mitigated; and
- d) potential impacts to industrial, manufacturing or other uses are minimized and mitigated.

As a sensitive land use, the Subject Application is required to avoid the potential for potential adverse effects on future residents. If avoidance is not possible, then there is a

requirement that the long term viability of Sanofi's both existing and planned uses are protected by (among other things) demonstrating an identified need for the proposed use. It is not at all clear that there is a demonstrated need for high density residential development to be located at Dufferin and Steeles, on a property that is also within a Provincially Significant Employment Zone.

Policy 1.2.6.1 and the principle of the separation of major facilities and sensitive land uses is also reflected in policy 3.4.21 of the City of Toronto Official Plan, and the Subject Applications are also not in conformity with that policy.

The PPS contains general policies for Employment Areas, including policy 1.3.2.2 which direct that such areas be planned to maintain long term operations and economic viability of the planned use and function of these areas.

The PPS also requires (in policy 1.1.1 c)) that development and land use patterns which may cause public health and safety concerns be avoided.

*Proposals do not conform with A Place to Grow*

*A Place to Grow* also contains policies which recognize the importance of the protection of industry from the encroachment of sensitive land uses. Policy 2.2.5.8 requires that the development of sensitive land uses will, in accordance with provincial guidelines, avoid or where avoidance is not possible, minimize and mitigate adverse impacts on industrial uses that are vulnerable to encroachment. In this case, the applicable provincial guidelines include the D-6 series which relates to compatibility between industrial and sensitive land uses, as well as NPC-300. As noted in the staff report, Sanofi's operations are a Class III industry. Provincial guidelines require a 300 metre separation distance to the nearest sensitive land use. Staff correctly state "It is not possible for the site at 1875 Steeles Avenue West to provide a 300-metre separation" in keeping with the D-6 Guidelines.

The D Series Land Use Compatibility Guidelines (which the province has recently confirmed continue to apply for the purposes of provincial policy conformity) require that for the purposes of determining the separation of sensitive uses from industry, measurements are to be taken from lot line to lot line. The Subject Applications are located on lots that are between 90-100 metres from the Subject Property, and therefore do not meet the separation distance criteria and do not conform with either the D series Guidelines or *A Place to Grow*.

We note that when the City approved the re-designation and re-zoning on the Sanofi Property to allow expansion, restrictions were included in the zoning that reflected the setbacks recommended in the D-6 Guidelines based on the existing residential uses. The same approach should be applied here – limiting sensitive uses near the existing and expanding Sanofi operations.

*Proposals do not conform with the City Official Plan*

The Subject Applications propose high density residential development on parcels of land that are effectively an island of a Mixed Use designation that are surrounded by Core and General Employment designations.<sup>3</sup>

If approved, the Subject Applications would represent a pocket of high density residential uses, at a height and density that would not be consistent with the surrounding area, both with respect to the surrounding employment uses as well as the adjacent low rise Neighbourhood. The location of these densities and heights on this corner is not in conformity with the policies of the Official Plan with respect to compatibility of uses and the location of buildings of this height and density.

*Noise incompatibility*

The Land Use Compatibility report submitted as part of the application confirms that the noise levels at the proposed residences cannot meet provincial guidelines for noise in an urban area. The proposed solution of designating the property as “Class 4” creates a living environment where the noise levels are permitted to be 10db louder, which is effectively twice as loud. Sanofi currently receives regular noise complaints from the existing low density residential area. In keeping with the requirements of its Environmental Compliance Approval, Sanofi is required to respond to and investigate every complaint, and advise the province if a non-compliance issue has been identified. Every noise complaint takes time and resources to address. The introduction of thousands of new residents in close proximity to its operations has the potential to divert considerable resources from Sanofi’s operations to address noise complaints. The fact that the night time noise limits set by provincial guidelines are not met for almost all of the locations studied by the applicant’s consultants is indicative of the potential disruption caused not only to Sanofi’s operations, but to the living environment of future residents.

Designating the site as Class 4 is not a noise mitigation measure. A Class 4 designation changes the standards and allows louder noises – it does not decrease the noise in any way. A Class 4 designation also does not mean that new residents cannot file complaints. Sanofi anticipates that the addition of 960 units (representing several thousand new residents) will result in a significant increase in noise complaints and the diversion of resources to respond to them.

---

<sup>3</sup> An extract from Map 16 of the Toronto Official Plan is attached.



### *Future operations*

Provincial policy expressly speaks not only to existing operations of major facilities, it also protects the long term viability of such operations. If new sensitive uses are approved and built in the form of 960 new units, Sanofi's ability to respond to technological advances in research and manufacturing will be permanently limited. The impediment on Sanofi's ability to innovate and expand could limit Canada's presence in the bio-manufacturing, research and bio-technology space. Its ability to expand will be limited by the presence of the sensitive uses. While it is adjacent to low density residential today, sensitive uses in towers create noise receptors at height, which creates a more limited ability to increase production or capacity, or compete globally for new R&D and biomanufacturing mandates in the future. Many countries are actively pursuing biomanufacturing facilities within their borders, and any limiting factors (such as adjacent high rise residential) decreases the potential for new investment at this site.

### *Site specific concerns*

In addition to issues in relation to overall land use compatibility, Sanofi is particularly concerned about the security of its sensitive operations. The research and manufacturing of biopharmaceuticals and vaccines is frequently the subject of scrutiny, opposition and protest. Its existing operations take this into consideration through the use of measures to protect information about its day to day operations. The location of hundreds of new residential units with a 24/7 overlook of its sensitive facilities undermines Sanofi's ability to ensure its ongoing and expanding vaccine research and manufacturing facilities are secure, given the strategic importance of the Sanofi Property, nationally and globally, for vaccine manufacturing and future pandemic readiness.

As part of its expanding operations, Sanofi is also investing in the upgrade of significant servicing infrastructure to ensure it has access to sufficient and reliable water services and electricity to support its current and expanded operations. Sanofi wishes to ensure that this investment does not result in development that it is opposed to, and that it continues to have unrestricted access to the upgraded infrastructure that it is paying to have installed.

### *Conclusion*

While Sanofi is supportive of efforts to address the housing crisis in the City and province, the need to build housing must not be at the expense of existing industry, especially where public health and pandemic preparedness operations occur. The significant investment of Sanofi's global organization and public resources in Sanofi's operations cannot and should not be undermined by the introduction of new sensitive uses adjacent to its vital and expanding operations. Sanofi therefore urges Council to not follow the staff recommendation, and refuse the applications before it.

OSLER

We ask that we be given notice of any decision with respect to these applications.

Yours very truly,

A handwritten signature in black ink, appearing to read "Chris Barnett". The signature is fluid and cursive, with a prominent flourish at the end.

Chris Barnett  
Partner

Cc: Sanofi Pasteur Limited  
Anne Benedetti – Goodmans LLP, counsel for the applicant

Attachments:

- 1: Office of the Prime Minister – press release dated May 30, 2024
- 2: Office of the Premier – press release dated May 30, 2024
- 3: Aerial photograph
- 4: Extract from Map 16, Toronto Official Plan

May 30, 2024

Toronto, Ontario

Vaccines save lives. During the COVID-19 pandemic, millions of Canadians came together, rolled up their sleeves and got their shots. And because of this teamwork, we got through the pandemic. But as we look back on the past few years, one thing is clear – we need to make more vaccines here in Canada, and we need to be able to make them fast.

Today, the Prime Minister, Justin Trudeau, attended the official opening of Sanofi's new state-of-the-art Vaccine Manufacturing Facility in Toronto, Ontario. Backed by a federal investment of \$20 million, the facility will be one of the most advanced vaccine manufacturing facilities in the world.

As the largest biomanufacturing facility in Canadian history, it will help the company expand the production of its life-saving vaccines. It will produce whooping cough, tetanus, and diphtheria vaccines for Canada and 60 international markets. And it will create over 200 good-paying jobs as well as support and maintain over 1000 other jobs in Ontario.

We're investing in biomanufacturing, enabling breakthrough science, creating jobs, and producing the life-saving medicines that'll keep Canadians healthy, right here in Canada. It's a win for public health, a win for science, a win for our innovators and researchers, and a win for Canadian families.

And we're not stopping there. This is just the first of two advanced vaccine manufacturing facilities the company is building in Toronto, Ontario. With a \$415 million investment from our [Strategic Innovation Fund \(https://ised-isde.canada.ca/site/strategic-innovation-fund/en\)](https://ised-isde.canada.ca/site/strategic-innovation-fund/en), we're helping Sanofi build a new end-to-end flu vaccine manufacturing facility. Once operational, this facility will be able to produce enough vaccine doses to protect our entire population within six months of a pandemic flu strain being identified by the World Health Organization. This will make sure we're better prepared for health emergencies, better protected against outbreaks, and better placed to get vaccines to Canadians, faster.

Strengthening our biomanufacturing and life sciences sector across the country will help re-establish Canada's vaccine manufacturing capability, get them to families faster, and give our health scientists a fair chance to make groundbreaking discoveries – all while growing the economy and creating good jobs.

## Quotes

“Vaccines save lives. That’s why we’ll be producing a lot more of them in Canada, including flu vaccines. Sanofi’s two new facilities in Toronto will create good-paying jobs, protect the health and well-being of Canadians, and give our scientists, innovators, and researchers a fair chance to succeed.”

— The Rt. Hon. Justin Trudeau, Prime Minister of Canada

“Our government is pleased to support Sanofi as they expand their footprint in Ontario. This new state-of-the-art facility is another vote of confidence in our workers and our growing life sciences sector, helping to ensure people in Ontario and around the world have increased access to life-saving vaccines when they need them.”

— The Hon. Doug Ford, Premier of Ontario

“Today’s announcement represents a significant milestone in our vision to rebuild our domestic biomanufacturing sector. By attracting such significant foreign investments, our government is developing an industry and expertise that will help Canada contribute to global needs and be better prepared for a range of health threats, including future pandemics. These manufacturing facilities are building an important expertise in Canada by creating and maintaining highly skilled jobs for Canadians.”

— The Hon. François-Philippe Champagne, Minister of Innovation, Science and Industry

“Protecting the health and safety of people in Canada is one of our government’s top priorities. With this new facility, we can strengthen our domestic biomanufacturing capacity and improve health outcomes for Canadians.”

— The Hon. Mark Holland, Minister of Health

“With the resurgence of infectious diseases, the capacity to develop and produce vaccines in Canada is critical. In strengthening Canada's vaccination supply, we can better help protect our loved ones, our communities, and the most vulnerable among us.”

— The Hon. Ya’ara Saks, Minister of Mental Health and Addictions and Associate Minister of Health

“Sanofi’s Facility in Toronto adds to Canada’s roster of pharmaceutical manufacturers who are creating vaccines for a variety of life-threatening diseases and illnesses. The Government of Canada is pleased to support this project with \$20 million that will bolster our domestic vaccine production, grow our biomanufacturing and life sciences sectors, and create good jobs.”

— The Hon. Filomena Tassi, Minister Responsible for the Federal Economic Development Agency for Southern Ontario

“We at Sanofi are proud to have delivered Canada’s largest, state-of-the-art new vaccine manufacturing facility, which symbolizes our unwavering dedication to innovation and scientific advancement. As a leader in prevention, Sanofi will significantly increase capacity to protect children and adults world-wide against pertussis (whooping cough), diphtheria, and tetanus vaccines. In addition, Sanofi continues building its new flu and pandemic preparedness facility which will be operational in 2027. We thank the federal, provincial, and municipal governments for their crucial collaboration and for their commitment to public health.”

— Stephanie Veyrun-Manetti, Country Lead Canada and General Manager Specialty Care, Sanofi

## Quick Facts

- Through Canada’s Biomanufacturing and Life Sciences Strategy, the Government of Canada has invested \$2.2 billion across 38 projects in the biomanufacturing ecosystem (<https://ised-isde.canada.ca/site/biomanufacturing/en/biomanufacturing-projects-underway>), including:
  - Biovectra (Prince Edward Island): \$39.8 million to expand mRNA and plasmid DNA manufacturing, enabling them to offer end-to-end manufacturing for mRNA vaccines.
  - AbCellera (British Columbia): \$175.6 million to support antibody discovery for clinical testing, in collaboration with Eli Lilly, and construction of a facility in Vancouver; \$225 million to create a state-of-the-art biotech campus and make significant upgrades to its existing facilities in Vancouver.
  - The Government also entered into an agreement with Moderna, which is building a state-of-the-art manufacturing facility in Laval, Quebec, that will be able to produce up to 100 million mRNA vaccine doses annually.

- Sanofi's newly opened Vaccine Manufacturing Facility in Toronto, Ontario, was supported by a \$20 million investment from FedDev Ontario, provided as a repayable contribution through the Advanced Manufacturing Fund. The Government of Ontario also supported the project with a \$50 million investment through its Jobs and Prosperity Fund, and the City of Toronto is providing tax incentives to Sanofi through the Imagination, Manufacturing, Innovation and Technology incentive program.
- With a total cost of \$925 million, the construction of Sanofi's second facility in Toronto is also supported by an investment of \$455 million from the company and \$55 million from the Government of Ontario. Once up and running, it will produce the company's Fluzone High-Dose Vaccine for its Northern Hemisphere campaign.
- The Strategic Innovation Fund (<https://ised-isde.canada.ca/site/strategic-innovation-fund/en>), supports research, development, and commercialization of new products that pave the way for Canada as a global innovation leader and attract investments that create jobs. It was launched in Budget 2017 to ensure Canada remains a top destination for businesses to invest, grow, and create jobs.
- Earlier this month, nearly \$574 million in Government of Canada funding was announced to support 19 projects at 14 research institutions across Canada, through Stage 2 of the integrated Canada Biomedical Research Fund and Biosciences Research Infrastructure Fund.
- To advance the next generation of cutting-edge research, Budget 2024 proposes investments in vaccine research and development, including:
  - \$30 million over three years, starting in 2024-25, to support the completion of the University of Saskatchewan's Centre for Pandemic Research at the Vaccine and Infectious Disease Organization in Saskatoon, Saskatchewan. This investment will enable the study of high-risk pathogens to support vaccines and therapeutic development, a key pillar in Canada's Biomanufacturing and Life Sciences Strategy.
- Sanofi is a global healthcare company and leader in the development of drugs and vaccines. It employs more than 100,000 people globally in 100 countries, with entities in Canada employing over 2,000 people, including almost 80 per cent of jobs related to vaccines. Sanofi's heritage in Canada dates back to 1914, with the majority of its Canadian operations located in Toronto, Ontario. Over the past 110 years, the company's site has been home to many advances in Canadian and global public health.
- Sanofi is the top investor in biopharmaceutical manufacturing and research and development in Canada. As part of the Government's investment in Sanofi's new

flu and pandemic readiness facility, Sanofi will invest at least \$79 million a year in Canada's research and development sector.

- Sanofi has signed on to the Government of Canada's 50 – 30 Challenge (<https://www.ic.gc.ca/eic/site/icgc.nsf/eng/07706.html>), pledging to increase the representation and inclusion of diverse groups within their workplace by attaining gender parity and significant representation of under-represented groups within their senior leadership.
- Flu pandemics historically occur every 11 to 41 years, making it critical for Canada to have domestic biomanufacturing capacity for pandemic flu vaccines.

## **Associated Links**

- Sanofi (<https://www.sanofi.com/en/canada>)
- Strategic Innovation Fund (<https://www.ic.gc.ca/eic/site/125.nsf/eng/home>)
- Canada's Biomanufacturing and Life Sciences Strategy (<https://ised-isde.canada.ca/site/biomanufacturing/en/canadas-biomanufacturing-and-life-sciences-strategy>)
- Emergency preparedness and response (<https://www.canada.ca/en/public-health/services/emergency-preparedness-response.html>)
- Budget 2024: Fairness for Every Generation (<https://budget.canada.ca/2024/home-accueil-en.html>)

NEWS RELEASE

## Ontario Celebrates Launch of Canada's Largest Biomanufacturing Facility

Sanofi's new facility will significantly increase domestic production of life-saving vaccines

May 30, 2024

[Economic Development, Job Creation and Trade](#)

---

TORONTO — Today, the Ontario government joined Sanofi to celebrate the grand opening of their new, \$800 million vaccine manufacturing facility at its Toronto campus. The new building, spanning approximately 200,000 square feet, will produce pediatric and adult vaccines for pertussis (whooping cough), diphtheria and tetanus, significantly increasing the country's production of life-saving vaccines for domestic and global markets.

"Our government is pleased to support Sanofi as they expand their footprint in Ontario," said Premier Doug Ford. "This new state-of-the-art facility is another vote of confidence in our workers and our growing life sciences sector, helping to ensure people in Ontario and around the world have increased access to life-saving vaccines when they need them."

Sanofi's new facility builds on the company's expansive footprint in Ontario, which includes a full spectrum of R&D, manufacturing, clinical trials, regulatory, distribution and commercial operations. As part of Sanofi's 2,000 employees in Canada, the facility will employ 200 people and is supported by federal, municipal and provincial governments including a \$50 million investment from the province of Ontario.

"Ontario is a life sciences superpower, with a long history of cutting-edge innovation and discovery," said Vic Fedeli, Minister of Economic Development, Job Creation and Trade. "Sanofi's new facility represents a strategic link in our province's biomanufacturing supply chain and is a welcomed addition to Ontario's growing life sciences ecosystem — the largest in the country."

Sanofi is also building a second new facility at its Toronto campus to increase production of the Fluzone High-Dose Influenza Vaccine, a flu vaccine specifically formulated for people 65 years and older.



"Under the leadership of Premier Ford, Ontario has become a hub of health care innovation and technology that is connecting more people to the care they need, when they need it," said Sylvia Jones, Deputy Premier and Minister of Health.

"Sanofi's new state-of-the-art vaccine manufacturing facility in Toronto is championing made-in-Ontario vaccinations that will build healthier communities in our province, and around the world, for years to come."

As part of the government's life sciences strategy, the province is investing \$15 million through the Life Sciences Innovation Fund and \$100 million through the Ontario Together Fund to help establish Ontario as a global biomanufacturing and life sciences hub. Over the past three years, Ontario has attracted over \$3 billion in investments from life sciences companies and global biomanufacturers.

---

#### Quick Facts

- Ontario's life sciences sector is a key economic driver, employing more than 72,000 people in high-value jobs across 2,000 firms, and exporting over \$12 billion in goods to markets around the world.
  - Ontario is a central hub for health research talent that includes 19 of Canada's top 40 research hospitals. These facilities are leading ground-breaking trials on local, national and international levels.
  - The province's life sciences strategy, [Taking Life Sciences to the Next Level](#), is establishing Ontario as a global biomanufacturing and life sciences hub. The goal is to grow the sector by targeting 85,000 high-value jobs by 2030, a 25 per cent increase from 2020.
  - To support the next stage of the province's life sciences strategy, our government established a Life Sciences Council that has supported the creation of jobs and encourages the adoption of Ontario made innovations to improve health care.
  - Each year, the Sanofi's Toronto campus produces vaccines that protect over seven million Canadians against infectious diseases and exports vaccines to over 60 countries.
-

## Quotes

"Vaccines save lives. That's why we'll be producing a lot more of them in Canada, including flu vaccines. Sanofi's two new facilities in Toronto will create good-paying jobs, protect the health and well-being of Canadians, and give our scientists, innovators, and researchers a fair chance to succeed."

**- The Rt. Hon. Justin Trudeau  
Prime Minister of Canada**

"Companies around the world are taking notice of Ontario's thriving life sciences ecosystem, access to top tier talent, competitive business costs and advanced innovations. Thanks to investments like this one from Sanofi, our province's life sciences and biomanufacturing sector continues to grow and provide job opportunities through made-in-Ontario solutions."

**- Nina Tangri  
Associate Minister of Small Business**

"Sanofi remains committed to investments and innovation that improve people's lives around the world. Our new vaccine manufacturing facility at our Toronto Campus will help ensure children and adults, in Canada and in 60 countries, are protected from pertussis (whooping cough), diphtheria and tetanus. Our dedication to innovation and scientific advancement is unwavering and we continue building our new influenza and pandemic preparedness facility which will be operational in 2027. We thank the federal, provincial and municipal governments for their crucial collaboration and for their commitment to public health."

**- Stephanie Veyrun-Manetti  
Country Lead Canada and General Manager Specialty Care, Sanofi**

---

## Additional Resources

- [Taking Life Sciences to the Next Level](#)
  - [2024 Ontario Budget: Building a Better Ontario](#)
  - [Sanofi Canada](#)
-

## Related Topics

### Business and Economy

Information about Ontario's economy and how to do business here. Includes economic development opportunities, research funding, tax credits for business and the Ontario Budget. [Learn more](#)

### Jobs and Employment

We've got the resource and supports to help connect job seekers with employers. [Learn more](#)

### Media Contacts

#### Vanessa De Matteis

Minister's Office

[Vanessa.DeMatteis@ontario.ca](mailto:Vanessa.DeMatteis@ontario.ca)

#### Media Relations

Communications Branch

[economy.media@ontario.ca](mailto:economy.media@ontario.ca)

---

Accessibility

Privacy

© King's Printer for Ontario, 2012-2024

---

Attachment 3 - Aerial Photo



1875 Steeles

Sanofi Property

